Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
UniPharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$13.4
2024-10-29
Market Capitalization
NT$493.5 M
2024-10-29
Revenue
NT$88.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 15, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 161.7M | 154.3M | 138.6M | 105.4M | 128.1M | 103.2M | 93.5M | 88.4M |
| Cost of goods sold | 89.3M | 79.0M | 67.9M | 35.3M | 48.1M | 46.7M | 42.9M | 39.7M |
| Gross profit | 74.0M | 76.5M | 72.4M | 71.4M | 81.0M | 60.2M | 53.7M | 51.3M |
| Gross profit margin, % | 58.3% | 57.5% | 58.0% | |||||
| Operating expense total | 87.7M | 91.9M | 80.2M | 99.5M | 95.5M | 78.3M | 74.4M | 85.9M |
| Depreciation and amortization | 6.0M | 11.2M | 11.2M | 10.8M | 5.4M | 5.5M | 7.0M | 7.0M |
| EBITDA | (13.7M) | (15.4M) | (7.8M) | (28.2M) | (14.5M) | (18.2M) | (20.7M) | (34.5M) |
| EBITDA margin, % | -17.6% | -22.1% | -39.1% | |||||
| EBIT | (19.7M) | (26.6M) | (17.2M) | (38.9M) | (9.2M) | (23.7M) | (27.8M) | (41.7M) |
| EBIT margin, % | -23.0% | -29.8% | -47.1% | |||||
| Interest income | 1.4M | 1.8M | 1.5M | 1.2M | 1.3M | 2.0M | 1.9M | 2.1M |
| Interest expense | 163.0K | 141.0K | 99.0K | 39.0K | 14.0K | 108.0K | 99.0K | |
| Pre tax profit | (40.4M) | (25.0M) | (55.4M) | (74.4M) | (7.0M) | (21.8M) | (24.8M) | (40.5M) |
| Net Income | (40.4M) | (25.0M) | (55.4M) | (74.4M) | (7.0M) | (21.8M) | (24.8M) | (40.5M) |